Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

Lingaku Lee, Tetsuhide Ito, Hisato Igarashi, Masami Miki, Nao Fujimori, Ken Kawabe, Robert T. Jensen, Yoshihiro Ogawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose and schedule modification. Methods: Sixteen patients with advanced PNET treated with sunitinib were reviewed retrospectively. Efficacy was evaluated by progression-free survival (PFS) and objective tumor response. Toxicity profile was assessed regularly. Correlation between relative dose intensity (RDI) and treatment period was also evaluated. Results: The median PFS was 25.8 months, and the probability of PFS at 1-year was 92%. The objective response rate and clinical benefit rate were 44% and 69%, respectively. The common adverse drug reactions (ADRs) were hand-foot syndrome (88%), neutropenia (75%), leucopenia (75%), and diarrhea (63%). Due to the development of severe ADRs, 81% required dose reduction and 31% discontinued sunitinib treatment, respectively. Prolonged treatment period was significantly correlated with decreased RDI (Spearman r = − 0.57, P = 0.022). The median RDI among 9 patients whom continued sunitinib more than 1 year was 49%. Conclusions: Sunitinib showed significant clinical benefit in Japanese patients with advanced PNET in the real-world clinical setting. Successful management of ADRs with appropriate dose reduction and interruption can enable long-term continuation of sunitinib.

Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalCancer chemotherapy and pharmacology
Volume81
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Neuroendocrine Tumors
Tumors
Appointments and Schedules
Drug-Related Side Effects and Adverse Reactions
Disease-Free Survival
Hand-Foot Syndrome
Pharmaceutical Preparations
Leukopenia
Neutropenia
Toxicity
sunitinib
Diarrhea
Therapeutics
Safety
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. / Lee, Lingaku; Ito, Tetsuhide; Igarashi, Hisato; Miki, Masami; Fujimori, Nao; Kawabe, Ken; Jensen, Robert T.; Ogawa, Yoshihiro.

In: Cancer chemotherapy and pharmacology, Vol. 81, No. 1, 01.01.2018, p. 163-169.

Research output: Contribution to journalArticle

@article{a440f961e9914fb1ba6e9107b1e7e340,
title = "Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors",
abstract = "Purpose: This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose and schedule modification. Methods: Sixteen patients with advanced PNET treated with sunitinib were reviewed retrospectively. Efficacy was evaluated by progression-free survival (PFS) and objective tumor response. Toxicity profile was assessed regularly. Correlation between relative dose intensity (RDI) and treatment period was also evaluated. Results: The median PFS was 25.8 months, and the probability of PFS at 1-year was 92{\%}. The objective response rate and clinical benefit rate were 44{\%} and 69{\%}, respectively. The common adverse drug reactions (ADRs) were hand-foot syndrome (88{\%}), neutropenia (75{\%}), leucopenia (75{\%}), and diarrhea (63{\%}). Due to the development of severe ADRs, 81{\%} required dose reduction and 31{\%} discontinued sunitinib treatment, respectively. Prolonged treatment period was significantly correlated with decreased RDI (Spearman r = − 0.57, P = 0.022). The median RDI among 9 patients whom continued sunitinib more than 1 year was 49{\%}. Conclusions: Sunitinib showed significant clinical benefit in Japanese patients with advanced PNET in the real-world clinical setting. Successful management of ADRs with appropriate dose reduction and interruption can enable long-term continuation of sunitinib.",
author = "Lingaku Lee and Tetsuhide Ito and Hisato Igarashi and Masami Miki and Nao Fujimori and Ken Kawabe and Jensen, {Robert T.} and Yoshihiro Ogawa",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00280-017-3482-7",
language = "English",
volume = "81",
pages = "163--169",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

AU - Lee, Lingaku

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Miki, Masami

AU - Fujimori, Nao

AU - Kawabe, Ken

AU - Jensen, Robert T.

AU - Ogawa, Yoshihiro

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose and schedule modification. Methods: Sixteen patients with advanced PNET treated with sunitinib were reviewed retrospectively. Efficacy was evaluated by progression-free survival (PFS) and objective tumor response. Toxicity profile was assessed regularly. Correlation between relative dose intensity (RDI) and treatment period was also evaluated. Results: The median PFS was 25.8 months, and the probability of PFS at 1-year was 92%. The objective response rate and clinical benefit rate were 44% and 69%, respectively. The common adverse drug reactions (ADRs) were hand-foot syndrome (88%), neutropenia (75%), leucopenia (75%), and diarrhea (63%). Due to the development of severe ADRs, 81% required dose reduction and 31% discontinued sunitinib treatment, respectively. Prolonged treatment period was significantly correlated with decreased RDI (Spearman r = − 0.57, P = 0.022). The median RDI among 9 patients whom continued sunitinib more than 1 year was 49%. Conclusions: Sunitinib showed significant clinical benefit in Japanese patients with advanced PNET in the real-world clinical setting. Successful management of ADRs with appropriate dose reduction and interruption can enable long-term continuation of sunitinib.

AB - Purpose: This study aimed to clarify the efficacy and safety of sunitinib in Japanese patients with pancreatic neuroendocrine tumors (PNET), especially by focusing on dose and schedule modification. Methods: Sixteen patients with advanced PNET treated with sunitinib were reviewed retrospectively. Efficacy was evaluated by progression-free survival (PFS) and objective tumor response. Toxicity profile was assessed regularly. Correlation between relative dose intensity (RDI) and treatment period was also evaluated. Results: The median PFS was 25.8 months, and the probability of PFS at 1-year was 92%. The objective response rate and clinical benefit rate were 44% and 69%, respectively. The common adverse drug reactions (ADRs) were hand-foot syndrome (88%), neutropenia (75%), leucopenia (75%), and diarrhea (63%). Due to the development of severe ADRs, 81% required dose reduction and 31% discontinued sunitinib treatment, respectively. Prolonged treatment period was significantly correlated with decreased RDI (Spearman r = − 0.57, P = 0.022). The median RDI among 9 patients whom continued sunitinib more than 1 year was 49%. Conclusions: Sunitinib showed significant clinical benefit in Japanese patients with advanced PNET in the real-world clinical setting. Successful management of ADRs with appropriate dose reduction and interruption can enable long-term continuation of sunitinib.

UR - http://www.scopus.com/inward/record.url?scp=85034629778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034629778&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3482-7

DO - 10.1007/s00280-017-3482-7

M3 - Article

VL - 81

SP - 163

EP - 169

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -